dr. jordi bruix on efficacy and safety of regorafenib in hcc after sorafenib
Published 7 years ago • 96 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:47
dr. jordi bruix on the impact regorafenib will have on liver cancer treatment
-
2:02
dr. bruix discusses the application of regorafenib in hcc
-
2:04
dr. bruix on regorafenib in second-line hcc
-
2:31
dr. bruix on the phase iii resorce trial in hcc
-
1:11
regorafenib vs sorafenib in the treatment of liver cancer
-
7:35
diagnosing hcc: when a biopsy is needed
-
3:48
clinical experience with regorafenib in hcc
-
1:10
real life analysis shows regorafenib improves survival upon progression on sorafenib in hcc
-
3:03
liver cancer stages
-
47:42
immune therapy in hepatocellular carcinoma
-
21:17
new treatment approaches for advanced, unresectable hcc
-
3:05
imbrave150: updated data on atezo plus bev versus sorafenib in hcc
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
2:01
qol analyses from rationale-301 of tislelizumab vs sorafenib in hcc
-
1:34
dr. finn on the promise of regorafenib for the treatment of hcc
-
8:29
incorporating regorafenib in the hcc treatment landscape
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
2:12
hepatocellular carcinoma: immunotherapy after sorafenib
-
0:49
dr. daniele on impact of regorafenib in hcc
-
5:28
assessing response to sorafenib
-
1:51
managing side effects with regorafenib in hcc
-
5:59
frontline lenvatinib vs sorafenib in hcc